Vaccinex will present data at AACR showing pepinemab's unique mechanism in enhancing immunotherapy, correlating with clinical benefit in HNSCC and melanoma studies.

A distinct mechanism of action for pepinemab has been identified, resulting in the generation of ample and fully developed tertiary lymphoid structures (TLS). This has been associated with long-lasting clinical improvements in patients with head and neck squamous cell carcinoma (HNSCC) as well as in a neoadjuvant trial in melanoma. The correlation between the presence of mature TLS and sustained therapeutic effects has been observed in these studies.